Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group
Suzana Jordan, Jörg H.W. Distler, Britta Maurer, Dörte Huscher, Jacob M. Van Laar, Yannick Allanore, Oliver Distler*, Tore K. Kvien, Paolo Airo, Juan José Alegre Sancho, Lidia Ananjeva, Codrina Michaela Ancuta, Martin Aringer, Alexandra Balbir-Gurman, Francesco Paolo Cantatore, Paola Caramaschi, Emmanuel Chatelus, Veronica Codullo, Dominique Farge-Bancel, Rosario Foti
*Corresponding author for this work
- Zurich Center for Integrative Human Physiology (ZIHP)
- University of Erlangen–Nuremberg
- Charite - Universitatsmedizin Berlin
- Utrecht University
- Université Paris Descartes
- Spedali Civili of Brescia
- Hospital Universitario Dr. Peset
- VA Nasonova Institute of Rheumatology
- 'Grigore T. Popa' University of Medicine and Pharmacy
- Universitätsklinikum Carl Gustav Carus
- Rambam Health Care Campus
- University of Foggia
- Université de Strasbourg
- University of Pavia
- Università Politecnica delle Marche
- University of Tubingen
- University of Münster
- Aldo Moro University of Bari
- University of Milan
- Hospital Regional Universitario Jose Ma Cabral y Baez
- Alexandria University
- University of Giessen
- Rikshospitalet-Radiumhospitalet HF
- University of Medicine and Pharmacy
- La Sapienza University of Rome
- Ghent University
- University of Debrecen
- University Medical Centre
- Second University of Naples
- University of Basel
- KU Leuven
- Marmara University
- Unit of Internal Medicine
373
Link opens in a new tab
Citations
(Scopus)